Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The impact of cancer on diabetes outcomes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Arreskov, AB, Olsen, MÅ, Pouplier, SS, Siersma, V, Andersen, CL, Friis, S & de Fine Olivarius, N 2019, 'The impact of cancer on diabetes outcomes' BMC Endocrine Disorders, bind 19, nr. 1, s. 60. https://doi.org/10.1186/s12902-019-0377-0

APA

Arreskov, A. B., Olsen, M. Å., Pouplier, S. S., Siersma, V., Andersen, C. L., Friis, S., & de Fine Olivarius, N. (2019). The impact of cancer on diabetes outcomes. BMC Endocrine Disorders, 19(1), 60. https://doi.org/10.1186/s12902-019-0377-0

CBE

Arreskov AB, Olsen MÅ, Pouplier SS, Siersma V, Andersen CL, Friis S, de Fine Olivarius N. 2019. The impact of cancer on diabetes outcomes. BMC Endocrine Disorders. 19(1):60. https://doi.org/10.1186/s12902-019-0377-0

MLA

Vancouver

Arreskov AB, Olsen MÅ, Pouplier SS, Siersma V, Andersen CL, Friis S o.a. The impact of cancer on diabetes outcomes. BMC Endocrine Disorders. 2019 jun 11;19(1):60. https://doi.org/10.1186/s12902-019-0377-0

Author

Arreskov, Anne Beiter ; Olsen, Maria Å ; Pouplier, Sandra Sinius ; Siersma, Volkert ; Andersen, Christen L ; Friis, Søren ; de Fine Olivarius, Niels. / The impact of cancer on diabetes outcomes. I: BMC Endocrine Disorders. 2019 ; Bind 19, Nr. 1. s. 60.

Bibtex

@article{a28c72eccbde44b2a6310a94dff92faa,
title = "The impact of cancer on diabetes outcomes",
abstract = "BACKGROUND: Survival from many cancer types is steadily increasing, and as a result, a growing number of cancer patients will live with other chronic diseases, of which diabetes is one of the most prevalent. This study aims to describe the impact of cancer on health outcomes in patients with type 2 diabetes and to compare the effectiveness of a multifactorial intervention in diabetes patients with and without cancer.METHODS: The randomized controlled trial Diabetes Care in General Practice (DCGP) included 1381 patients newly diagnosed with type 2 diabetes. Patients were randomized to either six years of structured personal diabetes care or routine care. In a post hoc analysis, we followed patients for 19 years in Danish national registries for the occurrence of diabetes-related outcomes. We used Cox regression models to estimate hazard ratios for outcomes.RESULTS: At diagnosis 48 patients had cancer, and 243 patients were diagnosed with cancer during follow up. Patients with diabetes and cancer had excess all-cause mortality (HR 3.33; 95{\%}CI 2.72-4.06), as well as an increased incidence of myocardial infarction (HR 1.76; 95{\%}CI 1.29-2.39) and any diabetes-related outcome (HR 1.36; 95{\%}CI 1.07-1.71). The intervention reduced the risk of both these endpoints in patients without cancer. Furthermore, there was no statistically significant difference in the effectiveness of the intervention among patients with and without cancer.CONCLUSIONS: Diabetes patients with cancer had an increased risk of myocardial infarction and any diabetes-related outcome. The observed positive effect of structured personal diabetes care on clinical outcomes did not differ between patients with and without cancer. Attention to and prevention of diabetes complications in patients with both type 2 diabetes and cancer is warranted.TRIAL REGISTRATION: ClinicalTrials.gov NCT01074762 (February 24, 2010).",
keywords = "Aged, Denmark/epidemiology, Diabetes Mellitus, Type 2/epidemiology, Early Medical Intervention, Female, Follow-Up Studies, General Practice/statistics & numerical data, Humans, Incidence, Male, Middle Aged, Myocardial Infarction/epidemiology, Neoplasms/complications, Prognosis, Registries",
author = "Arreskov, {Anne Beiter} and Olsen, {Maria {\AA}} and Pouplier, {Sandra Sinius} and Volkert Siersma and Andersen, {Christen L} and S{\o}ren Friis and {de Fine Olivarius}, Niels",
year = "2019",
month = "6",
day = "11",
doi = "10.1186/s12902-019-0377-0",
language = "English",
volume = "19",
pages = "60",
journal = "BMC Endocrine Disorders",
issn = "1472-6823",
publisher = "BioMed Central Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - The impact of cancer on diabetes outcomes

AU - Arreskov, Anne Beiter

AU - Olsen, Maria Å

AU - Pouplier, Sandra Sinius

AU - Siersma, Volkert

AU - Andersen, Christen L

AU - Friis, Søren

AU - de Fine Olivarius, Niels

PY - 2019/6/11

Y1 - 2019/6/11

N2 - BACKGROUND: Survival from many cancer types is steadily increasing, and as a result, a growing number of cancer patients will live with other chronic diseases, of which diabetes is one of the most prevalent. This study aims to describe the impact of cancer on health outcomes in patients with type 2 diabetes and to compare the effectiveness of a multifactorial intervention in diabetes patients with and without cancer.METHODS: The randomized controlled trial Diabetes Care in General Practice (DCGP) included 1381 patients newly diagnosed with type 2 diabetes. Patients were randomized to either six years of structured personal diabetes care or routine care. In a post hoc analysis, we followed patients for 19 years in Danish national registries for the occurrence of diabetes-related outcomes. We used Cox regression models to estimate hazard ratios for outcomes.RESULTS: At diagnosis 48 patients had cancer, and 243 patients were diagnosed with cancer during follow up. Patients with diabetes and cancer had excess all-cause mortality (HR 3.33; 95%CI 2.72-4.06), as well as an increased incidence of myocardial infarction (HR 1.76; 95%CI 1.29-2.39) and any diabetes-related outcome (HR 1.36; 95%CI 1.07-1.71). The intervention reduced the risk of both these endpoints in patients without cancer. Furthermore, there was no statistically significant difference in the effectiveness of the intervention among patients with and without cancer.CONCLUSIONS: Diabetes patients with cancer had an increased risk of myocardial infarction and any diabetes-related outcome. The observed positive effect of structured personal diabetes care on clinical outcomes did not differ between patients with and without cancer. Attention to and prevention of diabetes complications in patients with both type 2 diabetes and cancer is warranted.TRIAL REGISTRATION: ClinicalTrials.gov NCT01074762 (February 24, 2010).

AB - BACKGROUND: Survival from many cancer types is steadily increasing, and as a result, a growing number of cancer patients will live with other chronic diseases, of which diabetes is one of the most prevalent. This study aims to describe the impact of cancer on health outcomes in patients with type 2 diabetes and to compare the effectiveness of a multifactorial intervention in diabetes patients with and without cancer.METHODS: The randomized controlled trial Diabetes Care in General Practice (DCGP) included 1381 patients newly diagnosed with type 2 diabetes. Patients were randomized to either six years of structured personal diabetes care or routine care. In a post hoc analysis, we followed patients for 19 years in Danish national registries for the occurrence of diabetes-related outcomes. We used Cox regression models to estimate hazard ratios for outcomes.RESULTS: At diagnosis 48 patients had cancer, and 243 patients were diagnosed with cancer during follow up. Patients with diabetes and cancer had excess all-cause mortality (HR 3.33; 95%CI 2.72-4.06), as well as an increased incidence of myocardial infarction (HR 1.76; 95%CI 1.29-2.39) and any diabetes-related outcome (HR 1.36; 95%CI 1.07-1.71). The intervention reduced the risk of both these endpoints in patients without cancer. Furthermore, there was no statistically significant difference in the effectiveness of the intervention among patients with and without cancer.CONCLUSIONS: Diabetes patients with cancer had an increased risk of myocardial infarction and any diabetes-related outcome. The observed positive effect of structured personal diabetes care on clinical outcomes did not differ between patients with and without cancer. Attention to and prevention of diabetes complications in patients with both type 2 diabetes and cancer is warranted.TRIAL REGISTRATION: ClinicalTrials.gov NCT01074762 (February 24, 2010).

KW - Aged

KW - Denmark/epidemiology

KW - Diabetes Mellitus, Type 2/epidemiology

KW - Early Medical Intervention

KW - Female

KW - Follow-Up Studies

KW - General Practice/statistics & numerical data

KW - Humans

KW - Incidence

KW - Male

KW - Middle Aged

KW - Myocardial Infarction/epidemiology

KW - Neoplasms/complications

KW - Prognosis

KW - Registries

U2 - 10.1186/s12902-019-0377-0

DO - 10.1186/s12902-019-0377-0

M3 - Journal article

VL - 19

SP - 60

JO - BMC Endocrine Disorders

JF - BMC Endocrine Disorders

SN - 1472-6823

IS - 1

ER -

ID: 59005480